Synopsis
Motivation:
Goals:
Approach:
Results:
367-02-003
ISMRM Abstract
Tumor microenvironment: Insights from multiparametric MRI in mouse models of pancreatic ductal adenocarcinoma
Accepted
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.
To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.
Log inReferences
1. 1. Adamska, A.; Domenichini, A.; Falasca, M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci 2017, 18, doi:10.3390/ijms18071338. [doi]
2. 2. Torphy, R.J.; Wang, Z.; True-Yasaki, A.; Volmar, K.E.; Rashid, N.; Yeh, B.; Anderson, J.M.; Johansen, J.S.; Hollingsworth, M.A.; Yeh, J.J.; et al. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol 2018, 2018, doi:10.1200/po.17.00121. [doi]
3. 3. Principe, D.R.; Underwood, P.W.; Korc, M.; Trevino, J.G.; Munshi, H.G.; Rana, A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021, 11, 688377, doi:10.3389/fonc.2021.688377. [doi]
4. 4. Hingorani, S.R.; Harris, W.P.; Beck, J.T.; Berdov, B.A.; Wagner, S.A.; Pshevlotsky, E.M.; Tjulandin, S.A.; Gladkov, O.A.; Holcombe, R.F.; Korn, R.; et al. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clin Cancer Res 2016, 22, 2848-2854, doi:10.1158/1078-0432.Ccr-15-2010. [doi]
5. 5. Cao, Y.; Haring, C.T.; Brummel, C.; Bhambhani, C.; Aryal, M.; Lee, C.; Heft Neal, M.; Bhangale, A.; Gu, W.; Casper, K.; et al. Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma. Clin Cancer Res 2022, 28, 350-359, doi:10.1158/1078-0432.Ccr-21-2338. [doi]
6. 6. Kinh Do, R.; Reyngold, M.; Paudyal, R.; Oh, J.H.; Konar, A.S.; LoCastro, E.; Goodman, K.A.; Shukla-Dave, A. Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminary Findings. Tomography 2020, 6, 261-271, doi:10.18383/j.tom.2020.00015. [doi]
7. 7. Hoffmann, E.; Masthoff, M.; Kunz, W.G.; Seidensticker, M.; Bobe, S.; Gerwing, M.; Berdel, W.E.; Schliemann, C.; Faber, C.; Wildgruber, M. Multiparametric MRI for characterization of the tumour microenvironment. Nature Reviews Clinical Oncology 2024, 21, 428-448, doi:10.1038/s41571-024-00891-1. [doi]
8. 8. Mayer, P.; Dinkic, C.; Jesenofsky, R.; Klauss, M.; Schirmacher, P.; Dapunt, U.; Hackert, T.; Uhle, F.; Hänsch, G.M.; Gaida, M.M. Changes in the microarchitecture of the pancreatic cancer stroma are linked to neutrophil-dependent reprogramming of stellate cells and reflected by diffusion-weighted magnetic resonance imaging. Theranostics 2018, 8, 13-30, doi:10.7150/thno.21089. [doi]
9. 9. Ghahremani, P.; Li, Y.; Kaufman, A.; Vanguri, R.; Greenwald, N.; Angelo, M.; Hollmann, T.J.; Nadeem, S. Deep Learning-Inferred Multiplex ImmunoFluorescence for Immunohistochemical Image Quantification. Nat Mach Intell 2022, 4, 401-412, doi:10.1038/s42256-022-00471-x. [doi]
Cite this abstract
http://echo.ismrm.org/p/ISMRM2026/367-02-003